NMPA
AnPac Bio Developing Multi-Cancer Testing Device Based on Biophysical Properties of Blood Components
Premium
The device uses the Chinese-American company's "cancer differentiation analysis" technology and may enable earlier, more robust cancer detection.
AnPac Bio Files Multi-Cancer Detection Device for Registrational Testing With China's NMPA
The company hopes to begin clinical testing of the device, designed to aid in the diagnosis of 11 cancers, in the first half of 2022.
OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval
The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators.
China NMPA Approves Illumina NextSeq 550Dx Sequencer for Genetic Testing and Diagnosis
The clinical next-generation sequencing instrument is Illumina's second to receive approval from China's National Medical Products Administration.
OpGen Posts 70 Percent Increase in Q3 Revenues Amid Shuffling of Portfolio
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
Feb 11, 2020
Feb 10, 2020
Luminex Q4 Revenues Rise 12 Percent
Apr 11, 2019